BioSpace News Archive

ERYTECH Pharma (Nasdaq & Euronext: ERYP),today announced a summary of its poster presentation at the 2021 ASH Annual Meeting evaluating GRASPA® (eryaspase) in acute lymphoblastic leukemia (ALL) as well as the acceptance of two abstracts evaluating eryaspase in advanced pancreatic cancer at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, presented a trial in progress poster on NKX019 for the treatment of relapsed and refractory B-cell malignancies at the 63rd Annual Meeting and Exposition of the American Society of Hematology.

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that the Company will be added to the Nasdaq Biotechnology Index, effective prior to market open on Monday, December 20, 2021.

Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines, today announced that it has acquired US-based Avidea Technologies, Inc. (“Avidea”).

Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to acquire OrthogenRx, Inc., an emerging leader in viscosupplementation therapies for the treatment of knee osteoarthritis (OA) pain, for a total consideration of $160 million.

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, announced that data on the activity and mechanism of BTM-3566, a novel, first-in-class oral compound that targets mitochondrial dynamics leading to cellular stress and tumor cell apoptosis, was presented in an oral session at the 63rd Annual Meeting of the American Society of Hematology.

Champions Oncology, Inc., a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced its financial results for its second quarter of fiscal 2022, ended October 31, 2021.

Endogena Therapeutics Inc., an endogenous regenerative therapeutics company, today announced that its largest shareholder and lead operating partner Rejuveron Life Sciences AG, has committed a further $20 million funding to progress treatments targeting degenerative diseases of the eye.

Global Gamma Delta Car T Cells Based Cancer immunotherapy Market To Surpass USD 4 Billion By 2026 Says Kuick Research.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has placed clinical holds on the investigational new drug applications (INDs) for the oral and implant formulations of islatravir (MK-8591).